
==== Front
Front Immunol
Front Immunol
Front. Immunol.
Frontiers in Immunology
1664-3224
Frontiers Media S.A.

10.3389/fimmu.2024.1476204
Immunology
Correction
Corrigendum: Genetic investigation of Nordic patients with complement-mediated kidney diseases
Rydberg Viktor

Aradottir Sigridur Sunna
Kristoffersson Ann-Charlotte

Svitacheva Naila
Karpman Diana *

Department of Pediatrics, Clinical Sciences Lund, Lund University, Lund, Sweden
Edited and Reviewed by: Francesca Granucci, University of Milano-Bicocca, Italy

*Correspondence: Diana Karpman, diana.karpman@med.lu.se
23 8 2024
2024
23 8 2024
15 147620405 8 2024
08 8 2024
Copyright © 2024 Rydberg, Aradottir, Kristoffersson, Svitacheva and Karpman
2024
Rydberg, Aradottir, Kristoffersson, Svitacheva and Karpman
https://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
A Corrigendum on Genetic investigation of Nordic patients with complement-mediated kidney diseases By Rydberg V, Aradottir SS, Kristoffersson A-C, Svitacheva N and Karpman D (2023). Front. Immunol. 14:1254759. doi: 10.3389/fimmu.2023.1254759 complement
atypical hemolytic uremic syndrome
C3 glomerulopathy
membranoproliferative glomerulonephritis
genes
section-in-acceptanceMolecular Innate Immunity
==== Body
pmcIn the published article, there was an error in Table 3 as published. Under the heading C3, rowc.4030-4C>G was under the ACMG classification stated as “P” when it should be “LB”. Under the heading CFHR2, row R141S, “c.423G>A” should have been written as “c.423G>T”. And finally, under the heading CLU, row K444Q, “c.1339A>C” should be corrected to “c.1330A>C”. The corrected Table 3 and its caption appear below.

Table 3 Variants in C3G patients included in this study.

Variant or deletion	Nucleotide shift	Type of variant	dbSNP	Domain	Minor Allele frequency	Functional studies	ACMG classification	Reference	
CFH	
D693N a	c.2077G>A	Missense	rs148403790	SCR12	0.0001592		Conflicting	(48)	
Q950H	c.2850G>T	Missense	rs149474608	SCR16	0.003911	NPE	LP	(45, 51)	
N1050Yb	c.3148A>T	Missense	rs35274867	SCR18	0.01469	NPE	LB	(45, 54)	
S1209T	c.3625T>A	Missense	rs561146868	SCR20	0.00000398	–	LB	(48)	
C3	
K155Q	c.463A>C	Missense	rs147859257	MG2	0.002705	GoF	LP	(58, 59)	
V326Mc	c.976G>A	Missense	rs375264020	MG3	0.00004779	–	VUS	This study	
Q1061H	c.3183A>T	Missense	rs373054812	TED	0.00007704	–	VUS	This study	
E1516A	c.4547A>C	Missense	rs1019532370	C345C	0.00001193	–	VUS	This study	
W1631*	c.4893G>A	Stop	NA	C345C	–	LoF	P	(61)	
	c.4030-4C>G	Splice acceptor site	NA	Between CUB and MG8	–	–	LB	(55)	
CFI	
	c.1534+5G>T	Intronic splice	rs114013791	Intron 12	0.00866	–	–	(33)	
G328R	c.981G>A	Missense	rs144164794	Linker 2	–	LoF	LP	(55, 65)	
CD46	
A353Va,b	c.1013C>T	Missense	rs35366573	TM	0.01541	LoF, NFE	Conflicting	(33, 73)	
C5	
P233L	c.698C>T	Missense	rs531284110	MG3	0.0000252	–	VUS	(81)	
L354M	c.1060C>A	Missense	rs34552775	MG4	0.0055	–	B	(82)	
G385R	c.1153G>C	Missense	–	MG4	Unknown	–	–	This study	
CFHR1	
Deletion		Deletion			–	–	LB	(76)	
Exon 6 duplication		Duplication				–	LB	This study. Other duplications reported in (83)	
CFHR2	
R141S	c.423G>T	Missense	rs142929868	SCR2	0.002947	–	–	This study	
CFHR3	
Deletion		Deletion			–	–	–	(76)	
CFHR4	
Y43Fd	c.128A>T	Missense	rs202234955	SCR1	0.001747	–	LB	This study	
	c.799+3A>C	Intronic splice	Rs196876631	–	0.001286	–	LB	(82)	
CFHR5	
E163Kfs*10	c.485_486dup	Frameshift (insertion)	rs565457964	SCR3	0.006750	NPE	–	(77)	
E226Dfs*7	c.678del	Deletion	rs1438537910	SCR4	0.000007964	–	P	This study	
Y279N	c.835T>A	Missense	rs143240067	SCR5	0.0001274	–	Conflicting	(78)	
R356Hb	c.1067G>A	Missense	rs35662416	SCR6	0.01633	NPE	LB	(77, 84)	
CFP	
D299N	c.895G>A	Missense	rs61737993	TSP t1 5	0.001472	–	B	(85)	
CLU	
K444Q	c.1330A>C	Missense	rs2612311022	β-chain	0.0001026	-	-	This study	
PLG	
R89K	c.266G>A	Missense	rs143079629	PAN	0.006191	–	B	(48)	
R261H	c.782G>A	Missense	rs4252187	Kringle 2	0.002501	–	Conflicting	(80)	
a, Mentioned in the complement database (www.complement-db.org) with reference to (4). b, Minor allele frequency > 1% but this variant was previously associated with aHUS. c, Previously reported in the ClinVar database in association with age-related macular degeneration and aHUS. d, Previously reported in the ClinVar database in association with aHUS. CFH, Complement factor H; C3, Complement C3; CFB, Complement factor B; CFI, Complement factor I; CD46, CD46/Membrane cofactor protein; C5, Complement C5; CFHR1-5, Complement factor H related 1-5; CFP, Complement factor properdin; PLG, Plasminogen. Domains, SCR, Short consensus repeats; MG1-8, Macroglobulin domain 1-8; TED, Thiol ester-containing domain; C345C, C345C/NTR domain; CUB: C1r/C1s, Urchin embryonic growth factor, Bone morphogenetic protein 1; TM, Transmembrane protein; TSP t1, Thrombospondin type-1 1-5; PAN, Plasminogen-Apple-Nematode; NPE, No phenotypic effect; GoF, Gain of function; LOF, Loss of function (including low plasma concentration); VUS, Variant of unknown significance; LP, Likely pathogenic; LB, Likely benign; P, Pathogenic.

In the published article, there was an error in Supplementary Table 1. The C3 level of patient 314 was given as “normal” when it should have been written as “low”. The corrected Supplementary Material File has now been published.

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
